Wai Chun Bio-Technology Ltd. Statistics
Wai Chun Bio-Technology Ltd. (0660) Stock Statistics & Valuation Metrics
Total Valuation
Wai Chun Bio-Technology Ltd. has a market cap or net worth of HKD 165.25M. The enterprise value is HKD 198.91M.
- Market Cap
- HKD 165.25M
- Enterprise Value
- HKD 198.91M
Share Statistics
Wai Chun Bio-Technology Ltd. has 384,309,780 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 384,309,780
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Wai Chun Bio-Technology Ltd.’s return on equity (ROE) is 0.16 and return on invested capital (ROIC) is 16.46%.
- Return on Equity (ROE)
- 0.16
- Return on Assets (ROA)
- -0.07
- Return on Invested Capital (ROIC)
- 16.46%
- Return on Capital Employed (ROCE)
- -0.09
- Revenue Per Employee
- 6.18M
- Profits Per Employee
- -239.72K
- Employee Count
- 61
- Asset Turnover
- 1.76
- Inventory Turnover
- 6.04
Valuation Ratios
The current PE Ratio of Wai Chun Bio-Technology Ltd. is -11.11. Wai Chun Bio-Technology Ltd.’s PEG ratio is -0.07.
- PE Ratio
- -11.11
- PS Ratio
- 0.29
- PB Ratio
- -1.20
- Price to FCF
- -35.30
- Price to Operating Cash Flow
- 3.60
- PEG Ratio
- -0.07
Income Statement
In the last 12 months, Wai Chun Bio-Technology Ltd. had revenue of 377.17M and earned -14.62M in profits. Earnings per share was -0.08.
- Revenue
- 377.17M
- Gross Profit
- 36.00M
- Operating Income
- 5.36M
- Pretax Income
- -8.93M
- Net Income
- -14.62M
- EBITDA
- 17.90M
- Earnings Per Share (EPS)
- -0.08
Cash Flow
In the last 12 months, operating cash flow was 7.74B and capital expenditures -719.91M, giving a free cash flow of 7.02B billion.
- Operating Cash Flow
- 7.74B
- Free Cash Flow
- 7.02B
- Free Cash Flow per Share
- -0.03
Dividends & Yields
Wai Chun Bio-Technology Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -2.83%
- Earnings Yield
- -8.99%
Stock Price Statistics
- Beta
- 1.26
- 52-Week Price Change
- 119.39%
- 50-Day Moving Average
- 0.43
- 200-Day Moving Average
- 0.47
- Relative Strength Index (RSI)
- 51.44
- Average Volume (3m)
- 310.17K
Important Dates
Wai Chun Bio-Technology Ltd. upcoming earnings date is Sep 24, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 13, 2026
- Next Earnings Date
- Sep 24, 2027
- Ex-Dividend Date
- ―
Financial Position
Wai Chun Bio-Technology Ltd. as a current ratio of 0.39, with Debt / Equity ratio of -104.51%
- Current Ratio
- 0.39
- Quick Ratio
- 0.18
- Debt to Market Cap
- 3.98
- Net Debt to EBITDA
- 4.95
- Interest Coverage Ratio
- 0.39
Taxes
In the past 12 months, Wai Chun Bio-Technology Ltd. has paid 1.77M in taxes.
- Income Tax
- 1.77M
- Effective Tax Rate
- -0.20
Enterprise Valuation
Wai Chun Bio-Technology Ltd. EV to EBITDA ratio is 19.96, with an EV/FCF ratio of -63.66.
- EV to Sales
- 0.52
- EV to EBITDA
- 19.96
- EV to Free Cash Flow
- -63.66
- EV to Operating Cash Flow
- 13.97
Balance Sheet
Wai Chun Bio-Technology Ltd. has HKD 16.66B in cash and marketable securities with HKD 12.34B in debt, giving a net cash position of HKD 4.32B billion.
- Cash & Marketable Securities
- HKD 16.66B
- Total Debt
- HKD 12.34B
- Net Cash
- HKD 4.32B
- Net Cash Per Share
- HKD 11.24
- Tangible Book Value Per Share
- ―
Margins
Gross margin is 8.89%, with operating margin of 1.17%, and net profit margin of -1.21%.
- Gross Margin
- 8.89%
- Operating Margin
- 1.17%
- Pretax Margin
- -0.18%
- Net Profit Margin
- -1.21%
- EBITDA Margin
- 2.63%
- EBIT Margin
- 1.28%
Analyst Forecast
The average price target for Wai Chun Bio-Technology Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- 66.75%
- EPS Growth Forecast
- 87.02%
Scores
- Smart Score
- 7
- AI Score
- ―

